Drug intelligence / Profile preview

HRS-8829

Development stage: Phase 1
Lead developer: Beijing Suncadia Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

HRS-8829 is a **small molecule drug** developed for the treatment of **acute ischemic stroke**. Preclinical studies demonstrate that HRS-8829 can significantly reduce neurological deficit scores, decrease the extent of cerebral infarction and cerebral edema, inhibit inflammatory factor expression, improve neuronal survival, and suppress neuronal apoptosis. Its mechanism is presumed to involve neuroprotection and anti-inflammatory pathways, although its precise molecular target has not been publicly disclosed. The drug is formulated as an injectable concentrated solution for **intravenous administration** and is currently undergoing Phase 1 clinical trials[3][5].

Other names: HRS-8829HRS8829HRS 8829

Beyond the preview

Go deeper on HRS-8829.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-8829.

Explore the full profile